

3892 Del Amo Boulevard •Torrance, California 90503 (310) 214-0043 Web Site: www.bioscreen.com • E-Mail: info@bioscreen.com

CLINICAL EVALUATION OF THE EFFICACY OF A SKIN CARE PRODUCT IN IMPROVING SKIN CONDITIONS

FINAL REPORT

September 11, 2020

Revision #1 Date: September 11, 2020

SPONSOR:

Cosmetic Skin Solutions LLC 10580 North McCarran Boulevard Reno, NV 89503

TEST PRODUCT:

Supreme Phyto + Gel

STUDY NUMBER: BCS 20-213

PROJECT NUMBER: 1136641

RESEARCH STANDARD

This clinical study was conducted in accordance with the International Conference of Harmonization Tripartite Guideline on Good Clinical Practice, applicable FDA regulations/guidelines set forth in 21 CFR Parts 11, and 50 and standard practices of BioScreen Testing Services.

TABLE OF CONTENTS

		Page
I.	Summary of Results	4
II.	Study Objective	8
III.	Study Dates	8
IV.	Testing Facility	8
V.	Test Product	8
VI.	Test Product Handling	8
VII.	Adverse Events	9
VIII.	Study Results and Analysis	
	A. Study Subjects	10
	B. Skin Brightness L* (Chromameter)	11
	C. Skin Tone (Clinical Grading)	
	D. Skin Barrier (TEWL)	
	Appendix A.	14
	Appendix B	
	**	

I. SUMMARY OF RESULTS

Under conditions of the study a total of 26 healthy female subjects, 36-64 years of age, completed the clinical study evaluating the effectiveness of <u>Test Product: Supreme Phyto + Gel</u> to improve skin conditions.

A. <u>Skin Brightness L* (Chromameter)</u>


Note: Positive difference indicates an improvement in brightness.

Parameter	Week 4	Week 8
Mean Percent Difference from Baseline	-0.64%	0.41%
Percent of Subjects Improved	34.62%	46.15%

Bold values indicate statistical significance ($p \le 0.05$).

Clinical Findings:

• There was no statistically significant improvement in skin brightness from baseline at the week 4 and week 8 post-treatment intervals.



B. Skin Tone (Clinical Grading)


Parameter	Week 4	Week 8
Mean Percent Difference from Baseline	-2.80%	-5.59%
Percent of Subjects Improved	38.46%	46.15%

Note: Negative difference indicates in an improvement in appearance of skin tone

Bold values indicate statistical significance ($p \le 0.05$).

Clinical Findings:

• There was a statistically significant improvement in appearance of skin tone from baseline at the week 4 and week 8 post-treatment intervals.



C. Skin Barrier Function (TEWL)


Parameter	Week 4	Week 8
Mean Percent Difference from Baseline	8.03%	-9.96%
Percent of Subjects Improved	42.31%	76.92%

Negative difference indicates in an improvement skin barrier function

Bold values indicate statistical significance ($p \le 0.05$).

Clinical Findings:

- There was a statistically significant improvement in skin barrier function from baseline at the week 8 post-treatment interval.
- A statistically significant number of subjects demonstrated an improvement in skin barrier function from baseline at the week 8 post-treatment interval.



D. Post-Treatment Questionnaire (Week 4)

% of Subjects with Favorable Responses
88.46%
84.62%
88.46%
84.62%
84.62%
88.46%
65.38%
84.62%
80.77%
73.08%
61.54%
76.92%

Bold values indicate statistical significance ($p \le 0.05$).

E. Post-Treatment Questionnaire (Week 8)

Statement	% of Subjects with Favorable Responses
1. My skin looks smoother.	84.62%
2. The appearance of fine lines and wrinkles look smoother.	76.92%
3. My skin feels smoother.	96.15%
4. My skin feels more moisturized.	76.92%
5. My skin feels more hydrated.	80.77%
6. My skin feels more refreshed.	92.31%
7. My skin looks more radiant.	88.46%
8. My skin tone looks more even.	76.92%
9. My skin looks brighter.	76.92%
10. My skin looks revitalized.	73.08%
11. My skin looks more youthful.	61.54%
12. I would recommend this product to family and/or friends.	92.31%

Bold values indicate statistical significance ($p \le 0.05$).

II. STUDY OBJECTIVE

To evaluate the effectiveness of a skin care product to/for:

- Improve skin brightness
- Improve the appearance of skin tone
- Improve skin barrier function
- Consumer perception

III. STUDY DATES

The study began on June 15, 2020 and ended on August 21, 2020.

IV. TESTING FACILITY

BioScreen Clinical Services Division BioScreen Testing Services, Inc. 2300 W. 205th St. Torrance, CA 90501 PH: 424-307-5900

V. TEST PRODUCTS

Product Name	Number of	Date	Accession
	Samples	Received	Number
Supreme Phyto + Gel	60	11 May 2020	1136641

VI. TEST PRODUCT HANDLING

Test product that had been reviewed and approved for use by the Regulatory and Safety representatives of Cosmetic Skin Solutions LLC was tested.

Upon arrival at BioScreen Clinical Services (BCS) the test product was assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received and tests requested. Sample was retained for a period of 30 days beyond submission of final report. Sample disposition were conducted in compliance with appropriate federal, state and local ordinances.

Test Product Instructions

Each morning, apply 5 to 6 drops of product to a dry face, neck and décolleté using circular motion. Follow by applying SPF 30 Broad Spectrum sunscreen provided to face, neck and décolleté.

VII. ADVERSE EVENTS

There were no adverse events reported during the study period.

VIII. STUDY RESULTS AND ANALYSIS

A. Study Subjects

A total of 26 healthy female subjects consented, enrolled and completed the clinical study.

Table 1.Subject Demographics.

No.	Subject ID	Subject Initials	Age	Race
1	8823	GEK	52	С
2	14555	JFR	47	С
3	15743	KLM	58	С
4	17697	TMM	39	С
5	21920	T-N	56	А
6	22646	DLH	62	С
7	23260	TAS	38	AA
8	23624	PLC	53	AA
9	24588	BAM	60	С
10	26027	SKI	36	А
11	28140	VED	63	AA
12	28754	N-P	59	A
13	30657	YNV	39	Н
14	31343	S-0	59	А
15	31473	ISD	42	А
16	31488	Т-О	42	С
17	31534	DML	63	С
18	32644	TGS	50	А
19	32664	PMM	57	А
20	32669	SSU	52	А
21	32856	D-H	51	С
22	33468	BMB	64	С
23	33597	C-A	58	А
24	33902	G-T	50	С
25	35309	E-L	43	С
26	35316	GZJ	58	Н

A= Asian, AA= African American, C= Caucasian, H= Hispanic

B. <u>Skin Brightness L* (Chromameter)</u>

Interval	Mean ± SD
Baseline	59.17 ± 6.05
Week 4	58.79 ± 5.79
Week 8	59.41 ± 7.15

Table 2.Mean skin brightness values.

Table 3. Descriptive statistics of skin brightness differences from baseline.

Note:	Positive d	lifference	indicates	increase	in	skin	brightness.

Interval	Parameter	Skin Brightness Differences from Baseline
	Mean	-0.38
	SD	1.42
Week 4	% _{Change}	-0.64%
Week 4	р	NS
	%Improvers	34.62%
	р	NS
	Mean	0.24
	SD	2.64
Week 8	% Change	0.41%
WEEK O	р	NS
	%Improvers	46.15%
	р	NS

Bold values indicate statistical significance ($p \le 0.05$). NS= Not Significant.

C. Skin Tone (Clinical Grading)

Interval	Mean ± SD
Baseline	5.50 ± 1.28
Week 4	5.35 ± 1.19
Week 8	5.19 ± 1.22

Table 4.Mean skin tone scores.

Table 5. Descriptive statistics of skin tone differences from baseline.

эт (NT / 1.00	• • • •	, .	C 1 · ·
Note:	Negative difference	indicates an ir	nnrovement in an	pearance of skin tone.
1000.	i toguti to uniforonoc	marcules un n	inproveniene in up	peurunee or skin tone.

Interval	Parameter	Skin Tone Differences from Baseline
	Mean	-0.15
	SD	0.31
Week 4	% _{Change}	-2.80%
Week 4	р	0.042
	%Improvers	38.46%
	р	NS
	Mean	-0.31
	SD	0.43
Week 8	% _{Change}	-5.59%
week o	р	0.002
	%Improvers	46.15%
	р	NS

Bold values indicate statistical significance ($p \le 0.05$). NS= Not Significant.

D. Skin Barrier (TEWL)

Interval	Mean ± SD
Baseline	6.49 ± 1.89
Week 4	7.01 ± 2.35
Week 8	5.84 ± 2.38

Table 5. Descriptive statistics of skin barrier differences from baseline.

Note:	Negative	difference	indicates	increase	e in ski	n barrier.

Interval	Parameter	Skin Barrier Differences from Baseline
	Mean	0.52
	SD	2.25
Week 4	% Change	8.03%
week 4	р	NS
	%Improvers	42.31%
	р	NS
	Mean	-0.65
	SD	1.94
Week 8	% Change	-9.96%
VV CCK O	р	0.006
	%Improvers	76.92%
	р	0.044

Bold values indicate statistical significance ($p \le 0.05$). NS= Not Significant.

APPENDIX A

CLINICAL EVALUATION OF THE EFFICACY OF A SKIN CARE PRODUCT IN IMPROVING SKIN CONDITIONS

Study Number:	BCS 20-213
Principal Investigator:	Rania Ibrahim, Ph.D.
Sub-Investigator:	Brochelle Yazzie, B.S.
Sub-Investigator:	Jordan DeSantis, MHI
Sub-Investigator:	Livia Shoshani, B.S.
Testing Facility:	BioScreen Clinical Services Division BioScreen Testing Services, Inc. 2300 W. 205 th St. Torrance, CA 90501 PH: 602-277-1154
Sponsor:	

RESEARCH STANDARD

The conduct of this study will comply with the International Conference of Harmonization Tripartite Guidelines on Good Clinical Practice, applicable FDA regulations/guidelines set forth in 21 CFR Parts 11 and 50 and standard practices of BioScreen.

I. OBJECTIVE

To evaluate the effectiveness of a skin care product to/for:

- Improve skin brightness
- Improve the appearance of skin tone
- Improve skin barrier function
- Consumer perception

II. TESTING FACILITY

BioScreen Clinical Services Division BioScreen Testing Services, Inc. 2300 W. 205th St. Torrance, CA 90501

Investigator: Rania Ibrahim, Ph.D. PH: 602-277-1154

III. STUDY DURATION

The study will be completed within a 9-week period (including an approximate 1 week washout period and an 8 week product usage).

IV. STUDY DESIGN AND METHODS

Test Product

Supreme Phyto + Gel

Test Product Handling

Test products that have been reviewed and approved for use by the Regulatory and Safety representatives of Cosmetic Skin Solutions LLC will be tested. A sufficient quantity of samples of the above test product to allow for 35 subjects to use for the entire study duration will be received from Cosmetic Skin Solutions LLC prior to start of the study.

Upon arrival at BioScreen Clinical Services (BCS) the test product will be assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received and tests requested. Each individual sample of the test product will be weighed before and after use by the subject. This information will be recorded on the test product log-in form. Samples will be retained for a period of 30 days beyond submission of final report. Sample disposition will be conducted in compliance with appropriate federal, state and local ordinances.

Test Product Use Instructions

Each morning, apply 5 to 6 drops of product to a dry face, neck and décolleté using circular motion. Follow by applying SPF 30 Broad Spectrum sunscreen provided to face, neck and décolleté.

V. INFORMED CONSENT FORM, PHOTOGRAPHY RELEASE FORM, AND MEDICAL HISTORY FORM

Informed consent will be obtained from each volunteer prior to initiating the study describing reasons for the study, possible adverse effects, associated risks and potential benefits of the treatment and their limits of liability. Panelists will sign and date the informed consent document and a photography release form to indicate their authorization to proceed and acknowledge their understanding of the contents. Each subject will be assigned a permanent identification number and complete an extensive medical history form. These forms along with the signed consent forms will be available for inspection on the premises of BioScreen Clinical Services only. ^{21 CFR.} Ch.1. Part 50, Subpart B.

VI. SUBJECT SELECTION

Panel selection will be accomplished by advertisements in local periodicals, community bulletin boards, phone solicitation, electronic media or any combination thereof. Individuals will be admitted to study at the discretion of the Investigator or his designee based on medical history and findings on the pre-study interview and examination.

- 3. Number of Subjects: Approximately 33 healthy subjects meeting inclusion/exclusion criteria listed below will be enrolled to complete the study with a minimum of 25 subjects.
- 4. Age: 35-65
- 5. Sex: Female
- 6. Race: Unrestricted
- 7. Inclusion Criteria:
 - a. Individuals who, at baseline, are free of any dermatological or systemic disorder, which would interfere with the results, at the discretion of the Investigator.
 - b. Individuals in good general health.
 - c. Individuals who complete a preliminary medical history.
 - d. Individuals who will read, understand and sign an informed consent document.
 - e. Individuals who will be able to cooperate with the Investigator and research staff, have the test product applied according to the protocol and complete the full course of the study.
 - f. Individuals who have not participated in any study involving the same test site (face) for the past 15 days.
 - g. Individuals with visible uneven skin tone.
 - h. Individuals who will agree to discontinue use of personal care products (e.g. lotions, creams, serums) for the washout period and duration of the study, with the exception of those provided by BCS.
 - i. Individuals who agree to continue using approved cosmetics for the washout period

and duration of the study so long as they do not contain anti-aging ingredients. BCS staff will review cosmetics for approval.

- j. Individuals who agree not to sunbathe/tan and agree to avoid sun (UV) exposure as much as possible for the duration of the study.
- k. Individuals who agree to apply the sponsor provided sunscreen a minimum of 15 minutes prior to sun exposure, and to reapply every hour they remain outdoors.
- 6. Exclusion Criteria:
 - a. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
 - b. Individuals with an active (flaring) disease or chronic skin allergies (atopic dermatitis, eczema, psoriasis, acne), or had recently treated skin cancer (within the last 12 months).
 - c. Individuals with a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation.
 - d. Individuals with damaged skin at or in close proximity to test sites (e.g., sunburn, tattoos, scars, or other disfigurations).
 - e. Individuals who have any history, which, in the Investigator's opinion, indicates the potential for harm to the subject or could place the validity of the study in jeopardy.
 - f. Individuals who indicate that they are pregnant, planning a pregnancy or nursing.
 - g. Individuals who have been medically diagnosed with Type I Diabetes.
 - h. Individuals who have had any medical procedure, such as laser resurfacing, or plastic surgery to the test sites within the last 12 months (including Botox, Restylyn, or other fillers).
 - i. Individuals who are currently using or during the last 3 months have used, Retin A, or other Rx/OTC Retinyl A, or other astringent derived products or alpha hydroxyl acid treatments for photo-aging and fine lines/wrinkles.
 - j. Individuals who have a known history of hypersensitivity to any cosmetics, personal care products, and/or fragrances.
 - k. Individuals who are employees of BioScreen.

VII. EXPERIMENTAL TECHNIQUES

Bioinstrumental Method to Measure Skin Brightness

Skin color is measured quantitatively with a Chromameter. The instrument reports the color of reflected light in terms of L* (dark-light axis), a* (green-red axis) and b* (blue-yellow axis).

CR-400 Chromameter, Konica Minolta or Smart Probe 400 (IMS Inc, USA) will be used to measure skin brightness (L*). All 3 values, L*, a* and b* will be recorded and the L* values provided to the Sponsor. One measurement will be taken from the designated treatment sites at each measurement interval.

Bioinstrumental Method to Measure Skin Barrier Function²⁻³

Transepidermal water loss (TEWL) is a measure of skin barrier function. The evaporimeter probe has two sensors, which measures the vapor pressure gradient arising within the chamber and between the skin and the surrounding air.

TEWL will be measured using DermaLab Evaporimeter (Cortex Technology, Hadsund, Denmark). Decreases in TEWL post barrier disruption indicate an improvement in skin barrier function, such that less water is lost through the skin barrier.

TEWL measurements will be taken from the designated sites at each measurement interval.

Clinical Photography for Expert Grading for Appearance of Skin Tone 4-6

Photographs are taken in accordance with regulations provided by consumer protection agencies such as the Federal Trade Commission, the Food and Drug Administration and several other regulatory authorities. The following guidelines are followed: 1) Head position is the same in before and after photos, 2) Same lighting conditions are used and the distance from the camera is same for both, before and after picture, and 3) Same room and background is used for both before and after picture.

Clinical photographs of subjects' faces (frontal, left lateral and right lateral) will be taken and evaluated with Canfield VISIA CR system using the Standard 1 2 modality.

Photographs obtained will be evaluated for the appearance of skin tone using the following scale (half point increments will be allowed):

Scale: 0= None (Even skin tone), 1-3= Mild, 4-6= Moderate, 7-9= Severe (Uneven skin tone)

<u>Self-Assessment Questionnaire</u>

Each subject will be instructed to complete a self-assessment questionnaire provided by the Sponsor at week 4 and week 8 post-treatment intervals.

VIII. PROCEDURE

- 1. Subjects will report to the facility a minimum of five (5) days prior to study start.
- 2. Prior to beginning any study related activities, subjects will be given an informed consent form, photography release form, HIPAA form, experimental subject's bill of rights and code of conduct form to read.
- 3. Once subject has completed reading they will be interviewed, in private, by BioScreen to ensure their understanding of the aforementioned forms and be given the opportunity to ask any study related questions.
- 4. Subjects who agree to sign the aforementioned forms will be asked to complete a medical history form. Subjects declining to sign any of the forms will be dismissed from the study.

- 5. Subjects will be enrolled on the basis of the subject selection criteria. Subjects failing to meet criteria will be dismissed from the study.
- 6. Enrolled subjects will be given specific instructions prohibiting use of all personal care products (i.e. lotions, creams, serums, cleansers) on the test sites (face) for the entire study duration, including washout period.
- 7. Subjects will be instructed to continue use of all cosmetics (e.g. foundation, blush, eye makeup) as long as they do not contain anti-aging ingredients. Cosmetics will be inspected and approved by BCS staff to confirm it does not contain anti-aging ingredients.
- 8. Enrolled subjects will begin the washout period using only the provided soap (Neutrogena), sunscreen and approved cosmetics.
- 9. Following the 5 day washout period, subjects will return to the testing facility.
- 10. Subjects will be instructed to clean their face with a neutral cleanser and pat dry.
- Thereafter, subjects will equilibrate by remaining quietly seated for a minimum of fifteen (15) minutes in a room maintained at approximately 20-24°C and 30%-50% relative humidity. Temperature and humidity will be recorded during subject testing.
- 12. Following equilibration, subjects will have the below procedures/ measurements performed by trained BCS staff:


Baseline (pre-treatment)

- a. Clinical photography (frontal, left lateral, right lateral)
- b. Skin barrier function measurement at sites 1 and 2
- c. Skin brightness measurement at sites 3 and 4 See Figure 1 for schematic representation of test sites
- 13. Subjects will be dismissed from the testing facility and informed to return 4 weeks (±3 days) and 8 weeks (±3 days) post-treatment. Test product will be weighed for compliance. Subjects suspected of non-compliance will be dismissed from study participation. Subjects will be instructed not to use test product on the day of their scheduled visit.
- 14. Subjects will be instructed to clean their face with a neutral cleanser and pat dry.
- 15. Thereafter, subjects will equilibrate by remaining quietly seated for a minimum of fifteen (15) minutes in a room maintained at approximately 20-24°C and 30%-50% relative humidity. Temperature and humidity will be recorded during subject testing.
- 16. Following equilibration, subjects will have the below procedures/ measurements performed by trained BCS staff:

Week 4 / Week 8 (±3 days) (post-treatment)

- a. Clinical photography (frontal, left lateral, right lateral)
- b. Skin barrier function measurement at sites 1 and 2
- c. Skin brightness measurement at sites 3 and 4
- d. Post-treatment questionnaire
- 17. Subjects will return the remaining test product at week 8 and will be dismissed from the study.

Figure 1: Schematic representation of test sites



IX. ADVERSE EVENTS

An adverse event is any untoward medical occurrence, whether or not it is considered study related, including death, experienced by a subject. An event may consist of a disease, an exacerbation of a pre-existing illness or condition, an occurrence of an intermittent illness or condition, a set of related symptoms or signs, or a single symptom or sign.

A serious adverse event (SAE) as defined in the CFR 312.32 is "any experience that is fatal or life threatening, is permanently disabling, requires inpatient hospitalization, or is a congenital anomaly, cancer, or overdose". All serious adverse events will be reported to the sponsor within 24 hours of BCS notification.

Each adverse event must be promptly recorded and sufficiently documented by the Study Director in the source documentation and case report form even if the adverse event is assessed by the Study Director as unlikely to be related to the study. Adverse events are graded on a scale of severity (mild, moderate, severe, or lift threatening) and on a scale of relationship to the product (unknown, unrelated, unlikely, possible, probable, or definite). All adverse events will be reported to the Sponsor within five business days. All adverse events will be followed up until resolved, stabilized, the subject is lost to follow-up or the event is otherwise explained. All follow-up information should be reported to the Sponsor.

If, according to the Investigator, medical care is warranted, appropriate referrals will be made. BCS will follow all adverse events until resolution.

The contact information to report SAE is:

Rania Ibrahim, Ph.D. ribrahim@bioscreen.com Work: (602) 227-1154 Cell: (602) 689-2829

X. RISKS / DISCOMFORTS

Burning, stinging, itching, redness or irritation may occur at the test sites. There also may be risks and discomforts, which are not yet known.

XI. SUBJECT DISCONTINUATION

Criteria for the discontinuation of a subject during the study will include the following:

- 1. Significant protocol violation
- 2. Serious adverse experience
- 3. Request of the subject
- 4. Any unmanageable factor, in the Investigator's opinion, that may significantly interfere with the protocol or interpretation of results.

XII. PROTOCOL AMENDMENT

Any changes to the study protocol will be approved in writing by the client and BCS prior to implementation in the study.

XIII. DATA ANALYSES

Statistical analyses will test the hypothesis that the pre-treatment values of each parameter are statistically different from its post-treatment values. Statistical significance will be declared if the two-tailed *p*-value is ≤ 0.05 .

Subject scores for each parameter in questionnaires will be presented in a tabular format. The percentage of subjects responding in favor of the test product will be reported. Statistical analysis will be performed using a z-test. Statistical significance will be declared if the p-value is ≤ 0.05 .

XIV. STUDY REPORT

Final report will be issued to the sponsor within four weeks of study completion.

XV. DATA ARCHIVES

All original samples, raw data sheets, technician's notebooks, correspondence files, a copy of final report and remaining specimens will be maintained on the premises of the clinic in limited access marked storage files. A duplicate copy of the final report will be separately archived at BioScreen Testing Laboratories, Torrance, CA.

REFERENCES

- 1. 21 CFR. Ch.1. Part 50, Subpart B.
- 2. Leveque JL, Garson JC, de Rigal J. Transepidermal Water Loss from Dry and Normal Skin. *J Soc Cosmet Chem* 1979, 30: 333-343.
- 3. Elsner P, Berardesca E, Wilhelm KP, Maibach, HI. In *Bioengineering of the Skin*, Skin Biomechanics 2001. CRC Press, 117.
- 4. Arch. Dermatol., 128: 347-351, 1992.
- 5. Br. J. Dermatol., 130: 167-173, 1994.
- 6. Skin Pharmacol. Appl. Skin Physiol., 16: 100-107, 2003

APPENDIX B

A. <u>Skin Brightness L* (Chromameter)</u>

ID	Base	eline	Wee	ek 4	Week 8		
ID	Right Cheek	Left Cheek	Right Cheek	Left Cheek	Right Cheek	Left Cheek	
8823	62.4	61.3	61.4	61.6	67.0	65.4	
14555	63.6	62.8	63.6	63.2	66.9	66.1	
15743	59.9	60.2	60.7	58.7	58.2	60.3	
17697	60.9	58.2	59.6	58.6	58.6	58.3	
21920	64.5	65.1	62.5	64.1	65.8	64.8	
22646	64.5	63.7	61.8	59.4	63.7	60.8	
23260	47.2	46.2	49.4	46.2	44.3	39.6	
23624	44.8	42.7	43.8	43.1	47.2	45.6	
24588	63.8	64.1	65.1	62.5	66.7	66.6	
26027	61.8	60.1	61.2	59.3	59.4	58.0	
28140	41.1	42.5	43.9	42.0	40.8	38.1	
28754	62.7	62.8	61.9	60.3	57.4	57.8	
30657	60.7	58.5	55.9	57.3	59.9	58.0	
31343	62.3	61.9	63.0	62.3	63.1	65.9	
31473	60.1	60.6	63.9	60.6	59.3	58.4	
31488	61.5	60.5	61.0	60.9	61.5	61.4	
31534	58.8	59.8	59.3	59.2	65.0	63.0	
32644	62.3	62.9	64.1	63.7	62.8	61.9	
32664	59.0	60.3	58.6	61.0	61.6	56.7	
32669	60.0	61.7	58.9	61.4	63.5	61.9	
32856	61.3	61.8	61.8	60.5	61.4	61.7	
33468	60.3	62.3	62.6	62.9	65.8	65.9	
33597	55.5	52.2	52.3	51.4	52.5	52.0	
33902	57.4	56.3	58.6	58.1	58.3	57.8	
35309	64.5	62.5	61.6	59.8	66.2	65.0	
35316	62.2	62.7	60.9	61.5	60.7	60.8	

B. <u>Skin Tone (Clinical Grading)</u>

ID	Baseline	Week 4	Week 8
8823	7.0	6.5	6.0
14555	5.5	5.5	4.5
15743	7.0	6.5	6.5
17697	5.0	4.5	5.5
21920	6.0	6.0	6.0
22646	4.5	4.5	4.5
23260	4.5	4.5	4.0
23624	6.5	6.5	6.5
24588	4.0	4.0	3.0
26027	4.5	4.0	4.5
28140	5.0	5.0	5.0
28754	4.5	4.0	4.5
30657	5.0	5.0	5.0
31343	5.5	5.0	5.0
31473	3.5	3.5	3.5
31488	7.5	7.5	7.5
31534	8.0	8.0	7.5
32644	6.0	5.5	5.5
32664	5.0	5.0	5.0
32669	7.5	7.0	7.0
32856	4.0	4.5	3.5
33468	5.5	5.0	4.5
33597	5.5	5.5	5.5
33902	7.5	7.0	6.5
35309	4.0	4.5	4.0
35316	4.5	4.5	4.5

Scale: 0= None, 1-3= Mild, 4-6= Moderate, 7-9= Severe

C. Skin Barrier (TEWL)

ID	Base	eline	We	ek 4	Week 8		
ID	Right	Left	Right	Left	Right	Left	
8823	8.8	6.6	10.6	9.5	9.4	6.9	
14555	6.6	5.4	6.7	5.0	4.1	4.8	
15743	4.6	3.2	12.3	13.0	4.2	3.7	
17697	9.5	10.0	7.1	6.9	7.8	9.3	
21920	6.4	5.4	7.8	5.5	5.3	5.4	
22646	6.2	5.0	5.4	3.7	4.6	4.7	
23260	8.7	7.8	8.4	10.2	8.6	7.2	
23624	10.0	10.9	10.1	11.0	10.2	10.8	
24588	5.3	4.6	3.1	4.7	2.7	2.0	
26027	6.5	5.8	5.9	5.8	10.1	9.1	
28140	5.5	10.7	6.6	10.8	4.7	11.0	
28754	4.9	5.4	8.0	7.3	4.1	4.7	
30657	3.7	6.9	5.8	9.5	4.0	5.2	
31343	6.2	5.6	3.8	3.7	4.2	2.6	
31473	5.4	6.0	4.7	5.7	4.0	3.4	
31488	5.8	7.8	7.6	9.2	6.7	6.7	
31534	6.7	3.6	8.8	6.3	3.3	3.4	
32644	10.3	10.7	9.9	9.5	8.2	7.4	
32664	4.7	4.8	5.2	4.7	4.0	4.9	
32669	10.6	5.6	5.9	5.2	5.9	5.8	
32856	4.9	4.3	3.3	3.7	17.3	4.6	
33468	5.5	6.2	8.8	7.0	4.3	5.6	
33597	8.3	7.5	9.5	8.1	4.6	5.7	
33902	6.0	9.4	7.2	6.9	6.3	5.7	
35309	4.7	4.5	5.5	5.2	4.4	5.0	
35316	4.1	3.9	4.5	4.0	2.8	2.5	

D. <u>Post-Treatment Questionnaire (Week 4)</u>

ID	1. My skin looks smoother.	2. The appearance of fine lines and wrinkles look smoother.	3. My skin feels smoother.	4. My skin feels more moisturized.	5. My skin feels more hydrated.	6. My skin feels more refreshed.	7. My skin looks more radiant.	8. My skin tone looks more even.	∞ 9. My skin looks brighter.	ω 10. My skin looks revitalized.	11. My skin looks more youthful.	12. I would recommend this product to family and/or friends.
8823	3	3	3	3	2	3	3	3			2	3
14555	3	3	3	3	3	3	3	3	3	3	2	3
15743	2	3	2	3	3	3	2	2	2	2	2	2
17697	3	3	3	3	3	3	4	4	4	3	3	3
21920	2	3	2	3	3	3	3	3	3	3	2	3
22646	3	3	3	3	3	3	3	3	3	2	2	2
23260	3	3	4	4	4	3	4	3	3	3	4	4
23624	4	4	4	4	4	4	4	4	4	4	4	4
24588	2	2	2	2	2	2	2	2	2	2	2	2
26027	3	3	3	3	4	3	2	2	4	3	2	2
28140	4	4	3	3	3	4	4	4	4	4	4	4
28754	3	2	3	3	3	2	2	3	2	2	2	3
30657	3	3	3	3	3	3	3	3	3	3	3	3
31343	3	3	3	3	3	3	3	3	3	3	3	3
31473	3	3	3	3	3	3	3	3	3	3	3	3
31488	3	3	3	2	3	3	2	3	2	2	2	2
31534	3	3	3	3	3	3	3	3	3	3	3	3
32644	3	3	3	2	3	3	2	3	3	3	4	4
32664	3	3	3	3	3	3	3	3	3	3	3	3
32669	3	3	3	3	3	3	2	3	3	2	3	3
32856	4	4	4	4	4	4	4	3	4	4	4	4
33468	3	3	3	3	3	4	4	3	4	4	3	3
33597	3	4	4	4	2	3	2	3	3	3	4	4
33902	3	2	3	2	2	2	2	2	2	2	2	2
35309	3	2	3	3	3	3	3	3	3	3	3	3
35316	3	4	3	4	3	3	3	4	3	3	3	4

Scale: 4= Strongly Agree, 3=Agree, 2=Disagree, 1= Strongly Disagree

E. <u>Post-Treatment Questionnaire (Week 8)</u>

ID	1. My skin looks smoother.	2. The appearance of fine lines and wrinkles look smoother.	3. My skin feels smoother.	4. My skin feels more moisturized.	5. My skin feels more hydrated.	6. My skin feels more refreshed.	7. My skin looks more radiant.	8. My skin tone looks more even.	9. My skin looks brighter.	10. My skin looks revitalized.	11. My skin looks more youthful.	12. I would recommend this product to family and/or friends.
8823	3	3	3	2	2	3	3	2	3	2	2	3
14555	3	3	3	3	3	3	3	3	3	3	2	3
15743	2	2	3	3	3	3	2	2	2	2	2	2
17697	3	3	3	3	3	3	3	4	4	3	3	3
21920	2	3	2	4	3	3	3	2	3	3	2	3
22646	4	3	4	4	4	3	3	3	3	3	3	4
23260	4	3	4	4	4	4	4	3	4	4	4	4
23624	4	4	4	4	4	4	4	4	4	4	4	4
24588	1	1	3	3	3	3	3	3	2	2	2	3
26027	3	2	3	2	4	4	3	2	4	3	3	3
28140	3	3	3	3	3	3	3	3	3	3	3	3
28754	3	2	3	2	2	3	2	3	2	2	2	3
30657	3	3	3	2	2	2	3	2	2	2	2	3
31343	3	3	3	3	3	3	3	3	3	3	3	3
31473	3	3	3	3	3	3	3	3	3	3	3	3
31488	3	3	3	2	2	3	3	3	2	2	2	3
31534	3	3	3	3	3	3	3	3	3	3	3	3
32644	3	3	3	3	2	3	3	3	3	3	3	3
32664	3	3	3	3	3	3	3	3	3	3	3	3
32669	3	3	3	3	3	3	3	3	3	3	3	3
32856	4	4	4	3	4	4	3	4	3	3	3	3
33468	4	3	4	3	3	4	3	4	4	3	4	4
33597	4	4	4	4	3	4	4	4	4	4	4	4
33902	2	2	3	2	3	2	2	2	2	2	2	2
35309	3	2	3	3	3	3	3	3	3	3	2	3
35316	4	4	4	4	4	3	3	3	3	3	3	4

Scale: 4= Strongly Agree, 3=Agree, 2=Disagree, 1= Strongly Disagree

Livia Shoshani Clinical Manager

Steveparte

Steve Park Clinical Quality Assurance Lead

BioScreen Clinical Services Quote# 061029.r1 Page 29 of 29

BCS 20-213 Final Report